Our observation that the high concentration of TGFβ affects viability on long-term treatments is not in contrast with data from other studies, because the most common experimental setup in EMT investigation is the treatment with 10 ng/mL TGFβ only for short EMT induction (up to 48 h in pancreatic cancer [46,47,48]), with a lower concentration for longer induction (for example, breast cancer [49,50,51,52] and melanoma cancer [53]). The gene discussed is TGFB1; the disease is breast cancer.